Lameness Repair Company

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 10-17-2017

PRESS RELEASE

 

PetVivo HOldings Provides Shareholder Update

 

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to provide an update to our shareholders.

 

Information and skilled execution has always led the way to success. It is important to us, the management team of your company, be committed to informing all shareholders of the progress that has been made and is currently underway. Several major steps forward have been taken in the last few months, and there is potentially more to come in the next few.

 

First, I will address the management changes and additions. I accepted the position of CEO and Board Member in June. At the end of August, Cynthia Jenkins joined the company as CFO. The month of September saw the addition of David Deming and Peter Vezmar to the Board of Directors. October solidified the addition of Robin Young and Michael Haider to the Advisory Board. All of the business biographies of these individuals are posted on our website (www.petvivo.com) .

 

Second, as a reporting company, PetVivo has continued the effort to catch up on delinquent filings. It is projected that the final filing to bring the company current with the Securities and Exchange Commission will be submitted in early November. Once current our financial results will be available at most financial web portals that provide financial data.

 

PetVivo has a new home that is in final construction in Edina, Minnesota. Corporate offices, Research and Commercial production facilities will be ready for full operation on December 1st. The first commercial runs of “Kush” will be supporting the sales and marketing roll out scheduled to commence at the same time. We are currently assembling the sales and distribution team that will introduce our first product.

 

Financial support for these activities comes from the completion and oversold round of $525,000 of financing, which ended only last week. The funding is expected to complete the construction and fund the early stages of market and sales.

 

The stock (PETV) has experienced considerable appreciation over the last six months as confidence by investors has grown with the company achieving specific benchmarks. The practice of goal setting, short term and long term has become the norm among the management of your company. We continue to push forward each and every day to make out products a primary component in the canine, equine and eventually human solutions for the future.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

 

 

 

 

 

 

 

 

 

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

Created:
Monday, 10-09-2017
PRESS RELEASE

PETVIVO ADDS ROBIN YOUNG AND MICHAEL HAIDER TO ADVISORY BOARD

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Robin R. Young and Michael P. Haider have joined the Company’s Advisory Board.

Mr. Young is currently Chief Executive Officer of RRY Publications LLC and PearlDiver Technologies, Inc. RRY Publications is the publisher of Orthopedics This Week and organizer of educational seminars on such topics as Stem Cell Therapies, Clinical Research Issues and New Healthcare Technologies. RRY Publications reaches approximately 200,000 healthcare professionals monthly. PearlDiver is a data mining company which is used by both academic and corporate researchers to conduct research. PearlDiver has been cited in more than 75 peer reviewed journal studies. Previously, Mr. Young spent twenty-five years as a medical technology analyst with such firms as Piper Jaffray, Stephens, Inc. and HealthPoint Capital.

Mr. Young has been a podium speaker at the Foundation for Orthopedic Research, International Society for Advancement Spine Surgery, Laser Spine Institute, Johnson & Johnson Global R&D Congress, The Vatican and the Cedars Sinai Surgeon Conference. His subject topics have included Spine Surgery, Future of Orthopedics, Stem Cells, Regenerative Medicine and Allograft Surgical Products to name a few.

“PetVivo’s developing portfolio of advance biologic therapies is very exciting. I’m looking forward to contributing to the company’s development and success. The pace of medical innovation is accelerating and companies like PetVivo play a critical role in moving these important new technologies from the lab to the practitioner.”

Mr. Haider has over 40 years of medical business, finance and management experience, currently serving as the Co-Founder and CEO of CytoMedical Design Group LLC, a blood based stem cell research company. He previously served as the President and CEO of BioE LLC and BioE, Inc; President/Owner of Kodiak Restoration, a dental and medical equipment service company; Co-founder and President of PulseTrend, Inc., an ambulatory blood pressure device manufacturer; and as Vice President and Chief Financial Officer of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Mr. Haider held a variety of corporate finance positions at Medtronic, Inc., a leading provider of medical devices.

Mr. Haider and the companies he has led have been named one of the Twin Cities-based Finance and Commerce’s “Innovators of The Year”, received the Minnesota Tekne Award in the Emerging Biotechnology category and a Twin Cities Business, Biosciences Success Story. Since 2009, he has served as a member of National Marrow Foundation (“Be the Match”), New Technology Council and for the past decade he has been an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.

“I am pleased for the opportunity to contribute my business and technical experience to help the commercial success of PetVivo’s exciting technologies and new Kush product line. I am looking forward to working with the terrific team Wes and John are putting together, stated Mr. Haider.

“I have known Robin Young for over three generations. During that time, I have always been fascinated with his achievements. I am looking forward to his continued support and contributions. Mike Haider and I ran into each other quite by accident several years ago in London, England. It was only after conversing a while did we discover that we were both from Minnesota. Mike and Robin have decades of experience in regenerative medicine, more specifically stem cells. It is a privilege to have them working with us,” Said PetVivo’s CEO, Wes Hayne.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

 

GlobeNewswireOctober 3, 2017

NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) — “New To The Street,” a business television show, announces the addition of three exciting new clients to its list of profiled companies, PetVivo Holdings Inc. (PETV), Premier Biomedical, Inc. (BIEI), and Strikeforce Technologies, Inc. (SFOR); filming at show’s NYC broadcasting studios, Thursday, October 26, 2017.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/56f7f35b-3cf1-4308-b11b-2c61de050a7e

Mr. John Lai, President, PetVivo Holdings Inc., a company which developed an exciting technology to combat osteoarthritis in the canine and equine population. John plans to discuss PetVivo Holdings, Inc.’s technology, strategy and mission to deliver treatment for osteoarthritis, improving the lives of the many four- legged friends that families love.

Mr. Lai states, “I’m looking forward to discuss on ‘New To The Street’ how PetVivo’s disruptive technology can revolutionize the treatment and care of osteoarthritis in dogs and horses.  And, I’m excited for PETV to launch commercially its ‘Kush’ product and enter a $3 Billion plus market with this innovative technology.”

Also in the studio, William A Hartman, CEO of Premier Biomedical Inc. to discuss the company’s fight against pain with their phytocannabinoids products. He plans to discuss their recently launched website www.painreliefmeds.com, and how people with pain can find out about their phytocannabinoids products and find relief.

With the recent increases in cyber “hackings,” Mark Kay, CEO of Strikeforce Technologies, Inc. discusses his company’s place in the fight against cyber theft and data breaches. Strikeforce’s designed a suite of services to provide anonymity of your personal and financial information – ProtectID, GuardedID, and Mobiletrust products protect against thieves and hackers with the intent to steal personal information.

Viewers, please look out for the entire guest line-up the week of October 26, 2017. See which Companies profiled on “New To The Street’s” December Broadcast on Fox Business Network TV.  Watch for more news on show’s guests, Agritek Holdings, Inc. (AGTK), Financial Gravity (FGCO), DIBcoin cryptocurrency, Vystar Corp.(OTCPINK:VYST), Genoil, Inc.(GNOLF), MoneyOnMobile, Inc. (MOMT) and Kimberly Parry Organics Company (KPOC).

FMW Media Works Corp. (“New To The Street“) is a leading provider of business profiles and special corporate programming. FMW Media Works produces “New To The Street” which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. “New To The Street” airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations- www.NewToTheStreet.com.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. This press release should be considered in light of all filings of the Company that is contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact Information:

For “NEW TO THE STREET”
Adam Becker
(631) 465-0284
Adam.becker@newtothestreet.com

PetVivo Holdings
Wes Hayne, CEO
(612) 296-7305
info@petvivo.com
www.petvivo.com

Premier Biomedical Inc.
William A Hartman, CEO
(724) 633-7033
w.hartman@premierbiomedical.com
premierbiomedical.com

 

 

President John Lai Discusses Current Auditing State, the New Kush Product and the Company’s New Additions

President John Lai Discusses Current Auditing State, the New Kush Product and the Company’s New Additions

GlobeNewswire•September 28, 2017
Minneapolis, MN., Sept. 28, 2017 (GLOBE NEWSWIRE) — John Lai, President of PetVivo Holdings Inc. (OTCPink:PETV) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. In the beginning of the interview, Mr. Lai discusses the important addition of CEO Wes Hayne and how the auditing process of the company financials is coming to a close. Mr. Lai later discusses the new CFO and how Cindy Jenkins brings the proper controls with her to bring PetVivo current and how she will be able to keep it current with future filings. Mr. Lai also briefly discusses the new Kush commercial launch and later in the interview talks about when the revenues will hit the income statement after launch of this product. Furthermore, Mr. Lai highlights the addition of two outside independent directors to the company and elaborates on the experienced back ground that these two individuals will be bringing to PetVivo.
In closing, President John Lai states, “We feel we have put the right team together to execute and move this company forward for quite a period of time to manage the growth that we anticipate with the launch of commercial products that is disruptive to the industry of how you treat osteoarthritis.”
To listen to the full interview please click here or the following link:

Featured Interview: President & Chairman John Lai of PetVivo Holdings Inc. (OTCPink: PETV)

About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes, and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking Commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Source: Uptick Newswire

Press Release PetVivo Adds Two Independent Board Members

Press Release PetVivo Adds Two Independent Board Members

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 9-19-2017

PRESS RELEASE

 

PetVivo Adds David Deming and Peter Vezmar as Independent Directors

 

PetVivo Holdings, Inc. (www.petvivo.com) is pleased to announce that David Deming and Peter Vezmar will join the PetVivo PetVivo Board of Directors as independent members.

 

Peter Vezmar is currently the President and CEO of Marula Enterprises, a holding company founded to pursue investment opportunities primarily focused on targeted middle-market companies. Peter has more than thirty-five years of diverse experience in business management and strategy, corporate finance, IPOs, mergers and acquisitions, financial reporting, regulatory compliance, tax matters and corporate governance. Including a wide range of experience and understanding in many industries, including options/futures, life sciences/biotech, IT technologies, insurance, recycling, transportation/logistics, advertising, renewable energy and micro-brewery, among others.

“I look forward to joining the PetVivo team and working hard to realize the potential value of its innovative technology for shareholders,” commented Peter Vezmar.

David Deming has over thirty years of experience in client service, sales, marketing, operations and compliance.

David currently is a Partner at Asymmetric Capital Management, LLC. and he also serves as the Acting CEO, Treasurer and a Director at Wildfire 5G, Inc. Asymmetric Capital Management provides investment management services and the company is a pioneer in the build out of Hedged Beta Indices. Wildfire, 5G designs, builds, maintains, and operates next generation protected internet wireless networks that deliver a host of high-speed internet and telecommunication services to residential, educational, medical, hospitality and enterprise industries.

 

“I am very excited to be joining the Petvivo Board as they are a leading-edge growth company.  I look forward to working with their experienced, innovative senior management team,” stated David Deming.

 

“We are very pleased to have these two gentlemen join our Board of Directors. Both David and Peter have extensive experience operating and solving the problems that high growth businesses face. They add another level of expertise to our team,” noted Wes Hayne, the Company’s CEO.

 

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

8-K – Current report

Filed: 2017-09-19 AccNo: 0001477932-17-004579 Size: 65 KB
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits
Source: Petvivo SEC

Press Release New Hire Cynthia Jenkins

Press Release New Hire Cynthia Jenkins

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Wednesday, 8-30-2017

FOR IMMEDIAGE RELEASE

 

PETVIVO HOLDINGS, INC. ENGAGES Cynthia Jenkins AS CHIEF FINANCIAL OFFICER

 

PetVivo Holdings, Inc. (www.petvivo.com) is pleased to announce that Cynthia Jenkins will join the PetVivo team as the Company’s Chief Financial Officer (CFO). For more than forty years Ms. Jenkins has specialized in facilitating startup companies to build solid foundations in their financial and compliance/regulations departments.  She has extensive expertise in finance, accounting and treasury functions in addition to regulatory compliance and audit expertise.

 

“I am excited to have Cindy Jenkins join our team. Cindy has the experience that is difficult to find,” noted Wes Hayne, the Company’s CEO, “Her work ethic to hit deadlines is unparalleled and necessary in a growth company with a constant change in dynamics.”

 

Over her career, Ms. Jenkins has held the offices of CEO, President, Vice President, CFO, and Secretary/Treasurer and has been in upper management of small to mid-size broker-dealers and early stage companies.  She has extensive financial, compliance, and operational experience to facilitate new and existing firms grow and acclimate to the rules and regulations of the SEC and FINRA. She also specializes in AML audits, 3012 GAP Analysis testing, and documenting companies’ Written Supervisory and Compliance Procedures.  She holds Series 7, 24, 27, 52, 63, and 99 securities licenses.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

Press Release New Hire Wesley (Wes) Hayne

Press Release New Hire Wesley (Wes) Hayne

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Thursday, 7-20-2017

FOR IMMEDIAGE RELEASE

 

PETVIVO HOLDINGS, INC. HIRES WES HAYNE AS CHIEF EXECUTIVE OFFICER

 

Petvivo Holdings, Inc. (www.petvivo.com)  is pleased to announce its recent hire of Wesley Hayne, who will join the Petvivo team as Chief Executive Officer (CEO). Mr. Hayne will be taking over the position immediately. His immediate efforts will be to concentrate on the organizational and financial strategies of the company.

 

“I was attracted to the company by the potential of a regenerative biomaterial that may be used in a number of tissue applications; my interest was further enhanced when I was made aware of the biomaterial’s impact in the treatment of osteoarthritis. It was easy to accept the position once I had a complete understanding of how life changing this product can be for humans in addition to animals. The sustainability of the product once injected into dogs and horses is incredible. The “Particles”, in testing to date, have proven safe, with no side effects from the various applications.”

 

“We are very pleased to have Wes join the PetVivo team,” noted John Lai, who will now serve as the Company’s President. “Wes and I first worked together more than twenty-five years ago. Wes has an excellent track record of leading companies to commercial success and I am very confident he can do the same for PetVivo.”

 

Wes is an accomplished professional having served as CEO or President of several companies in start-up and/or high growth stages. He has extensive experience in strategic planning with an emphasis on finance, business development and sales/marketing.  He further has hands on expertise in investment banking, and structuring capital funding, divestures, and mergers and acquisitions.  Wes also has an extensive history in identifying business opportunities for expansion, motivating/managing sales forces, and providing decisive resolution to corporate problems.

 

“It is my intention to see this innovative technology penetrate numerous medical sectors, not only as a company introducing products to market itself, but also as a company that cultivates domestic and foreign licensing opportunities with strategic partners. In my opinion, the entire world is looking for this kind of advancement for treating many debilitating afflictions like osteoarthritis. To date there has been no real treatment for osteoarthritis, yet with age nearly all dogs, horses and humans are faced with it.”

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info@petvivo.com

Main: 612-296-7305

Direct: (763) 443-7272

 

Real Time Web Analytics